ACADNasdaqPharmaceutical PreparationsFiscal year ends December 31
ACADIA PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$19.80+0.68 (+3.56%)
Close on Oct 19, 2026
- Market cap
- $3.42B
- P/E (TTM)
- 9.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
91.7%−6.0 pts over 5 years
Operating margin
9.8%+74.7 pts over 5 years
Net margin
36.5%+100.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +11.9% | +27.5% | +19.4% | +165.7% | |
| Gross profit | +12.2% | +24.7% | +17.9% | – | |
| Operating income | -54.6% | – | – | – | |
| Net income | +72.7% | – | – | – | |
| EPS, diluted | +69.1% | – | – | – | |
| Free cash flow | -33.1% | – | – | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -75.6% | -42.5% | 39.9% | |
| Return on assets | -69.3% | -36.0% | 28.4% | |
| Current ratio | 12.87 | 6.77 | 3.83 | |
| Inventory turnover | – | 1.3× | 0.9× | |
| Capex to revenue | 8.7% | 1.7% | 0.4% | |
| Diluted shares | 116M | 0M | 170M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Acadia Pharmaceuticals generated $523.95M from operations and spent $6.39M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$523.95M
Used
$6.39M
Capital expenditure$6.39M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin36.5%
×Asset turnover0.78×
×Equity multiplier1.40×
=Return on equity, FY202539.9%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 36.5% | 0.78× | 1.40× | 39.9% |
| FY2024 | 23.6% | 0.99× | 1.66× | 38.9% |
| FY2023 | -8.4% | 1.09× | 1.61× | -14.7% |
| FY2022 | -41.8% | 0.80× | 1.37× | -45.9% |
| FY2021 | -34.7% | 0.65× | 1.27× | -28.7% |
| FY2020 | -63.7% | 0.56× | 1.18× | -42.5% |
| FY2019 | -69.4% | 0.51× | 1.12× | -39.9% |
| FY2018 | -109.6% | 0.48× | 1.14× | -60.2% |
| FY2017 | -231.7% | 0.26× | 1.11× | -67.8% |
| FY2016 | -1565.9% | 0.04× | 1.09× | -75.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
5of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$391.00M
- Cash generatingOperating cash flow above zero$109.84M
- Return on assets improvedROA up on the prior year30.2% → 32.9%
- Earnings backed by cashOperating cash flow above net income$109.84M vs $391.00M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose2.38 → 3.83
- No dilutionShare count did not rise166M → 170M
- Gross margin improvedGross margin up on the prior year91.46% → 91.69%
- More efficientAsset turnover rose1.28 → 0.90